To determine the usefulness of the AD CO model as a tool for drug testing, CAP COs were treated with BACE1 inhibitor IV (BSI), a β-secretase inhibitor, or compound E (CE), a γ-secretase inhibitor (Fig. 5a). Here, BACE1 is linked to Alzheimer disease.